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SCIENTIFIC OPINION 
Scientific Opinion on the safety of ‘heat-treated milk products fermented 
with Bacteroides xylanisolvens DSM 23964’ as a novel food1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA NDA Panel was asked to carry out the additional 
assessment for ‘pasteurised milk products fermented with Bacteroides xylanisolvens DSM 23964’ as a novel 
food (NF) in the context of Regulation (EC) No 258/97. Pasteurised or ultra-high-temperature-treated milk is 
used for the fermentation process with B. xylanisolvens DSM 23964. After fermentation the product is heat 
treated for one hour at 75 °C to ensure the absence of viable B. xylanisolvens DSM 23964. The Panel considers 
the information provided on the identity and characterisation of B. xylanisolvens DSM 23964 to be sufficient. 
The production process encompasses standard techniques used by the dairy industry, is sufficiently described by 
the applicant and does not give rise to safety concerns. The Panel considers that the information provided on the 
production process and on the content of vitamins B2 and B12 and furosine in heat-treated fermented milk 
products does not give rise to concerns regarding disadvantageous nutritional effects. The Panel considers that 
the microbiological data provided do not give rise to safety concerns. The Panel also notes that a pilot study and 
a RCT over six weeks with 140 volunteers receiving daily doses of a spray-dried heat-treated fermented milk 
product containing intakes of up to 1  1012 inactivated bacterial cells of B. xylanisolvens DSM 23964 were 
provided. No clinical effects related to the treatment were observed in the two studies. Although no information 
has been provided to conclude on the risk of allergic reactions caused by the NF, the Panel considers that it is 
unlikely that its allergenic potential is dissimilar to that of other fermented dairy products. The Panel concludes 
that the NF ‘heat-treated milk products fermented with B. xylanisolvens DSM 23964’ is safe for the proposed 
uses and at the proposed use levels.  
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA Panel) was asked to carry out the additional assessment for ‘pasteurised milk 
products fermented with Bacteroides xylanisolvens DSM 23964’ as a novel food (NF) in the context 
of Regulation (EC) No 258/97, taking into account the comments and objections of a scientific nature 
raised by Member States. 
The NF products pertaining to this application are low-fat and skimmed milk products that have been 
manufactured using B. xylanisolvens DSM 23964 as a starter culture, have been heat treated after 
fermentation and do not contain viable B. xylanisolvens bacteria. For the specification of the NF, the 
applicant proposes, the ‘absence of viable B. xylanisolvens’ by using a modified method for the 
detection and enumeration of Enterobacteriaceae (DIN EN ISO 21528-2) in addition to general 
microbiological analyses applicable for fermented milk products. 
Neither B. xylanisolvens DSM 23964 nor any other Bacteroides strain has a history of use in food 
production and consumption.  
Bacteroides spp. are commensal bacteria of the human intestinal microbiota, and the species 
B. xylanisolvens has been reported to be one of most abundant Bacteroides spp. in the human intestine. 
B. xylanisolvens DSM 23964 has been isolated from the faeces of a healthy human adult. In 2010, it 
was recognised as an independent strain. The sequence analysis of a 480-bp fragment of the 16S 
ribosomal RNA gene and DNA–DNA hybridisation analyses, as well as random amplified 
polymorphic DNA analysis, were used to identify this bacterium at species and strain level, 
respectively. The biochemical identification and characterisation of B. xylanisolvens DSM 23964 
included 12 enzymes and 6 metabolites. The Panel considers the information provided on the identity 
and the genotypic and phenotypic characteristics of B. xylanisolvens DSM 23964 to be sufficient. 
Pasteurised or ultra-high-temperature-treated (UHT) milk is used for fermentation with 
B. xylanisolvens DSM 23964. After fermentation, the product is heat treated for one hour at 75 °C to 
ensure the absence of viable B. xylanisolvens DSM 23964. The Panel notes that the production process 
encompasses standard techniques used by the dairy industry and considers that it is sufficiently 
described by the applicant and does not give rise to safety concerns. According to analyses provided 
by the applicant, heat treatment has no significant adverse effect on the content of vitamins B2 and B12 
and lysine. Based on the information provided on the production process and composition, the Panel 
considers that consumption of the NF is not nutritionally disadvantageous.  
The applicant provided studies evaluating the presence of antibiotic resistance and plasmids, potential 
virulence genes, extracellular enzymes and pathogenic factors, and the adhesion of B. xylanisolvens 
DSM 23964 to Caco-2 cells. The cepA gene conferring resistance to -lactam antibiotics was 
identified in the genomic DNA of this strain and plasmids were not detected. The Panel notes that 
resistance to -lactam antibiotics is widespread among Bacteroides spp. and that the cepA gene has not 
been reported to be associated with mobile elements (e.g. conjugative transposon) that mediate gene 
transfer. The Panel considers that the chromosomal location of cepA, the absence of detectable 
plasmids and the heat inactivation make it unlikely that horizontal gene transfer will occur from this 
bacterium. An abscess formation test with B. xylanisolvens DSM 23964 was negative. The Panel 
considers that the data provided do not give rise to safety concerns with regard to microbiological risks 
of the NF. 
According to the intake estimate performed by the applicant, the estimated number of inactivated 
(heat-treated) B. xylanisolvens cells ingested with fermented milk products was similar for the 
different age groups. On a kilogram body weight (bw) per day basis, intake was estimated to be 
highest in two- to five-year-old children, with mean and 90
th
 percentile values of 2  1010 cells/kg bw 
per day and 3.8  1010 cells/kg bw per day, respectively. These estimates are based on the conservative 
assumption that B. xylanisolvens DSM 23964 is used for all fermented milk products consumed. 
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The Panel also notes the results of a pilot study and a randomised controlled trial (RCT) in which 140 
adult volunteers received daily doses of a spray-dried heat-treated fermented milk product providing 
up to 1  1012 inactivated cells of B. xylanisolvens DSM 23964, which is above the 90th percentile 
intake of a conservative intake scenario. No haematological, immunological, gastrointestinal or other 
clinical adverse effects were observed related to the treatment in these two human studies.  
Although no information has been provided to allow conclusions to be drawn on the risk of allergic 
reactions caused by the NF, the Panel considers that it is unlikely that the allergenic potential of the 
NF is dissimilar to that of other fermented dairy products. 
The Panel concludes that the NF, heat-treated milk products fermented with B. xylanisolvens DSM 
23964, is safe for the proposed uses and at the proposed use levels.  
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 18 December 2012, the company Avitop GmbH submitted a request in accordance with Article 4 
of the Novel Food Regulation (EC) No 258/97 to place on the market pasteurised milk products 
fermented with Bacteroides (B.) xylanisolvens as a novel food. 
On 21 June 2013, the competent authority of Ireland (FSAI) forwarded to the Commission their initial 
assessment report, which came to the conclusion that pasteurised milk products fermented with B. 
xylanisolvens meet the criteria for acceptance of a novel food defined in Article (3)1 of Regulation 
(EC) No 258/97. 
On 4 September 2013, the Commission forwarded the initial assessment report to the other Member 
States. Several Member States submitted comments or raised objections. 
In consequence, a decision is now required by the Commission under Article 7(1) of Regulation (EC) 
No 258/97. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
 A clear product specification is lacking, and the production organism is not fully analysed 
genetically. Bacteroides xylanisolvens is presented as a commensal in the human intestine, but 
information regarding this organism in scientific literature seems to be rather scarce as yet. 
 There are no publications on the origin of the strain B. xylanisolvens DSM 23964 in contrast to 
the strain DSM 18836 (Chassard el al., 2008). The information on strain DSM 23964 is not as 
detailed as for the other one. The strain B. xylanisolvens DSM 23964 was only recently 
discovered and therefore little information is known and is closely related to Bacteroides 
ovatus which is potentially pathogenic in intra-abdominal infections. 
 It would be desirable to receive meaningful data on the comparability of the products in 
question with traditional products. 
 If pasteurisation of the milk products is unlikely to inactivate hydrolytic enzymes, enhanced 
colonic fermentation may increase the energy value of the consumed diet, which may not be 
beneficial to certain consumer groups.  
 Information regarding remaining hydrolytic enzyme activities in the final pasteurised food 
products containing B. xylanisolvens is lacking. These activities may enhance hydrolysis of 
other food components particularly those containing dietary fibre in consumers’ diet. The 
colonic fermentation may be enhanced to a level which may cause flatulence and intestinal 
discomfort in sensitive subjects. 
 Because of their enzyme make-up, Bacteroides species are suspected of being capable of 
converting precarcinogens into carcinogens. 
 Data for the EU on the anticipated intake of the NF including for children should be provided.  
 No information is presented regarding specific vulnerable groups within the population.  
 Possible allergenicity of heat-inactivated B. xylanisolvens has not been addressed. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION  
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission asks 
the European Food Safety Authority to provide a scientific opinion by carrying out the additional 
assessment for pasteurised milk products fermented with B. xylanisolvens as a novel food in the 
context of Regulation (EC) No. 258/97. 
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ASSESSMENT 
In accordance with Commission Recommendation 97/618/EC, pasteurised milk products fermented 
with B. xylanisolvens was allocated to class 2.2 (complex novel food from non-GM source which has 
no history of food use in the Community) by the competent authority of Ireland in its initial 
assessment report. The assessment of the safety of this novel food (NF) is based on data supplied in 
the original application, the initial assessment by the competent authority of Ireland (Food Safety 
Authority of Ireland, FSAI), the concerns and objections of the other Member States, and the 
responses of the applicant. The data are required to comply with the information required for novel 
foods of class 2.2, i.e. structured schemes I, II, III, IX, XI, XII and XIII of Commission 
Recommendation 97/618/EC. In the text, these structured schemes are covered in nine sections. This 
assessment concerns only the risk that might be associated with consumption, and it is not an 
assessment of the efficacy of pasteurised milk products fermented with Bacteroides xylanisolvens with 
regard to any claimed benefit. Council Directive 92/46/EEC of 16 June 1992 states in Annex C that 
‘Pasteurized milk must have been obtained by means of a treatment involving a high temperature for a 
short time (at least 71.7 °C for 15 seconds or any equivalent combination) or a pasteurization process 
using different time and temperature combinations to obtain an equivalent effect.’ In this opinion, the 
Panel therefore uses ‘heat treatment’ to describe the process of treatment at 75 °C for one hour, rather 
than ‘pasteurisation’, as proposed by the applicant. 
1. Specification of the novel food 
The novel food products pertaining to this application are low-fat and skimmed milk products that 
have been manufactured using B. xylanisolvens DSM 23964 as a starter culture, have been heat treated 
after fermentation and do not contain viable B. xylanisolvens bacteria. 
Both the applicant and the FSAI noted that ‘fermented milk products’ are not standardised 
compositionally in the EU, but noted the Codex standard for fermented milks including heat-treated 
fermented milks, concentrated fermented milks and composite fermented milk products for direct 
consumption or further processing (Codex Standard 243-2003; FAO, 2011). This standard specifies 
particular starter cultures for fermented milk products but also allows for the use of ‘other suitable and 
harmless microorganisms’. 
For the specification of the NF, the applicant proposes, the ‘absence of viable B. xylanisolvens’ by 
using a modified method for the detection and enumeration of Enterobacteriaceae (DIN EN ISO 
21528-2) in addition to general microbiological analyses applicable for fermented milk products. 
Regarding the modified DIN EN ISO 21528-2 analysis, the applicant stated that agar plates using 
Wilkins–Chalgren anaerobe agar CM0619 (Oxoid) were used with incubation for 48 hours at 37 °C, 
appropriate dilutions of B. xylanisolvens in Wilkins–Chalgren anaerobe broth CM0643 (Oxoid) were 
included as positive controls, and that all steps were conducted under anaerobic conditions.  
Identity and characterisation of B. xylanisolvens DSM 23964 
The B. xylanisolvens strain concerned was deposited by the applicant at the German Resource Centre 
for Biological Material (DSMZ) and has been assigned the reference number DSM 23964 (DSMZ, 
2010). The applicant notes that, before allocation of a reference number by the DSMZ, B. 
xylanisolvens DSM 23964 was referred to as B. xylanisolvens CTC1. This older designation was used 
in early study reports. The applicant provided a signed copy from the DSMZ that confirmed the 
acceptance of and viability of B. xylanisolvens CTC1 (DSM 23964) (DSMZ, 2010).  
According to the applicant, B. xylanisolvens DSM 23964 has been isolated from the faeces of a 
healthy adult human subject. Bacteroides spp. account for about one-quarter of all anaerobic 
microorganisms inhabiting the human colon (Salyers, 1984). Bacteroides xylanisolvens is a strictly 
anaerobic, Gram-negative species. The organisms are non-spore-forming, non-motile rods, which, 
unlike members of other Bacteroides spp., are unable to degrade starch (Chassard et al., 2008). 
Bacteroides xylanisolvens grows optimally at 38 °C and a pH value of about 6.8 under strictly 
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anaerobic conditions. It can utilise a variety of sugars, including lactose, and metabolises xylan to 
acetate, propionate and succinate. Bacteroides xylanisolvens DSM23964 was classified on the basis of 
its phenotypical and biochemical properties and by sequencing the 16S ribosomal RNA (rRNA) gene 
and by DNA–DNA hybridisation analyses (Ulsemer et al., 2012a). These authors constructed a 
phylogenetic tree covering the Bacteroides strain that is the subject of this application (DSM 23964), 
B. xylanisolvens DSM 18836 and 20 other characterised Bacteroides strains from other culture 
collections such as the American Type Culture Collection (ATCC), DSMZ or the Japan Collection of 
Microorganisms (JCM). In this analysis, a 480-bp sequence from the 16S rRNA of B. xylanisolvens 
DSM 23964 and B. xylanisolvens DSM 18836 showed 100 % similarity. The similarity to other related 
species was significantly lower: 97.5 %, 94.2 % and 92.2 % similarity to B. ovatus ATCC 8483, 
B  thetaiotaomicron ATCC 29148 and B. finegoldii DSM 17565, respectively. DNA–DNA 
hybridisation performed by the DSMZ Identification Service revealed 98.65 % similarity to B. 
xylanisolvens DSM 18836 and similarities of about 25–30 % to other investigated Bacteroides species 
(including B. ovatus ATCC8483). 
A random amplified polymorphic DNA (RAPD) analysis of B. xylanisolvens DSM 23964 and 
B. xylanisolvens DSM 18836 revealed different profiles, indicating that B. xylanisolvens DSM 23964 
is a strain distinct from B. xylanisolvens DSM 18836 (Culebras et al., 2012). 
The biochemical identification of B. xylanisolvens DSM 23964 was performed with rapid ID 32A and 
API 20A biochemical test kits (bioMerieux, Marcy l’Etoile, France) covering the activity of 12 
enzymes (N-acetyl-β-glucosaminidase, glutamic acid decarboxylase, α-fucosidase, indole production, 
arginine arylamidase, phenylalanine arylamidase, leucine arylamidase, tyrosine arylamidase, glycine 
arylamidase, histidine arylamidase, glutamyl glutamic acid arylamidase, serine arylamidase) and six 
metabolites (D-mannitol, salicin, glycerol, D-melezitose, D-sorbitol, D-trehalose). Bacteroides 
xylanisolvens DSM 23964 and B. xylanisolvens DSM 18836 showed an identical profile, and both 
were different from other Bacteroides spp. 
The applicant provided a comparison of some compositional parameters of skimmed milk fermented 
with B. xylanisolvens and of commercial milk products fermented with Lactobacillus reuteri, L. 
rhamnosus or yoghurt cultures, respectively (see Table 2, below). The Panel notes that information on 
the lactose content was not provided. 
The Panel considers the information provided on the identity and the genotypic and phenotypic 
characteristics of B. xylanisolvens DSM 23964 to be sufficient. 
2. Production process applied to the novel food 
The applicant provided details about the production of the B. xylanisolvens DSM 23964 starter culture. 
Sugars such as glucose and other fermentable sugars, such as xylan-containing plant materials, may be 
added to aid bacterial growth during fermentation. At the end of the fermentation process, the biomass 
culture is recovered, washed and concentrated about 50 times by ultracentrifugation. The 
B. xylanisolvens DSM 23964 pellets obtained may be used directly as a starter culture for milk 
fermentation or they may be frozen and lyophilised and stored for later use. The identity of the starter 
culture was confirmed by molecular analyses (species-specific polymerase chain reaction (PCR) and 
RAPD-PCR). Routine quality control procedures applied by the dairy industry are followed in the 
different steps of this process.  
In the production of milk products fermented with the B. xylanisolvens DSM 23964 starter culture, 
low-fat milk (< 1.8 % fat) or skimmed milk (< 0.3 % fat) is pasteurised or ultra-heat treated 
immediately before starting the fermentation process. After inoculation with the starter culture, the 
fermentation is run at 38.5 °C under constant gassing with carbon dioxide and without stirring for 14 
to 16 hours. The milk product is homogenised at the end of the fermentation process and then heat 
treated at 75 °C for one hour to inactivate the starter culture. For quality control purposes, samples are 
taken before and after the second heat treatment. The fermented milk product may then be either 
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packaged like a traditional liquid fermented milk product or spray dried for use as a fermented milk 
powder. Quality control tests, including microbiological tests in accordance with the European 
Pharmacopoeia, are conducted throughout the process to ensure the absence of contaminating 
microorganisms and to check the absence of viable B. xylanisolvens in the final product.  
The applicant also provided a study report on the effect of the heat treatment after fermentation of the 
milk with B. xylanisolvens DSM 23964 at either 75 °C for various times (15, 30, 60, 120, 180 seconds) 
or 65 °C for 30 minutes (Toutounian, 2008). Heat-treated milk before inoculation of B. xylanisolvens 
DSM 23964 was used as negative control. Heat-treated and fermented milk before the second heat 
treatment but after fermentation was used as positive control. No microbial colony could be observed 
on any of the samples heat treated after fermentation under cultivation conditions (Wilkins–Chalgren 
agar, anaerobic conditions). 
In response to a question raised by a Member State, the applicant answered that the standards (Good 
Manufacturing Practice, GMP) and quality control measures (Hazard Analysis and Critical Control 
Point, HACCP) that are applied in the production of the NF are up to date and that the compliance of 
the production of the NF with the applicable standards for food production will fall within the scope of 
the same rules and within the competence of the same authorities as the production of the 
corresponding traditional foods.  
The Panel notes that the production process encompasses standard techniques used by the dairy 
industry and considers that it is sufficiently described by the applicant and does not raise safety 
concerns. 
3. History of the organism used as a source  
Bacteroides spp. account for about one-quarter of all anaerobic microorganisms inhabiting the human 
colon (Salyers, 1984). Bacteroides spp. are largely non-pathogenic commensals, although certain 
strains of the species B. fragilis have been reported to be potentially pathogenic and toxigenic (Brook, 
1989; Sánchez et al., 2012).  
Bacteroides xylanisolvens is a regular commensal of the human intestinal microbiota (Marschal et al., 
2011; Ponnusamy et al., 2011; Zitomersky et al., 2011). Kulagina et al. (2012) reported that 
B. xylanisolvens, together with B. vulgatus and B. uniformis, were the most prevalent and abundant 
Bacteroides species in the faeces of 36 healthy subjects aged 1 – 33 years, in whom bacterial counts of 
these species were in the order of 8.3 – 9.9 lg colony-forming units (CFU)/g faeces. 
Neither B. xylanisolvens DSM 23964 nor any other Bacteroides strain has a history of use in food 
production and consumption. 
4. Anticipated intake/extent of the use of the novel food 
The applicant intends to market the NF in liquid and semi-liquid forms in fermented low-fat and 
skimmed milk products, i.e. fermented milks, buttermilks, yoghurts and yoghurt drinks, and as spray-
dried powder to be used like yoghurt powders, e.g. in fillings and coatings of cereals, cereal bars, fruits 
and nuts. The final heat-treated fermented milk products may also be supplemented with other 
ingredients such as sugars, flavours, fruit preparations and fibre. 
The intakes of non-fat milk solids were estimated using US consumption data. The applicant stated 
that equivalent European data were not available to him. The applicant considered a conservative 
scenario in which the NF was assumed to replace all the yoghurts, buttermilks and acidophilus milks. 
Based on the US National Health and Nutrition Examination Survey (NHANES) food intake data and 
the associated Food Commodity Intake Database of raw agricultural consumption data, mean daily 
intakes of non-fat solids from yoghurts, buttermilks and acidophilus milks for all survey participants 
(> 2 years of age) were estimated as 1.6 g per day rising to 6.3 g per day for the 90
th
 percentile 
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(Appendix A). Considering consumers only, the corresponding figures were 5.5 g per day and 15.3 g 
per day, respectively. 
The highest mean and 90
th
 percentile values for daily intakes were estimated for consuming children 
aged 2–5 years (6.4 g per day and 14.9 g per day, respectively) and for males aged 20 years or older 
(5.4 g per day and 17.4 g per day, respectively). On a per kilogram body weight per day basis, the 
highest daily intakes of all fermented non-fat milk solids combined were reported for children aged 2–
5 years (mean 0.38 g/kg bw per day; 90
th
 percentile 0.96 g/kg bw per day). When considering only 
yoghurt consumers, the highest mean and 90
th
 percentile intake on a per kilogram body weight per day 
basis was estimated for children aged 2–5 years (0.57 and 1.1 g/kg bw per day).  
In a second step, the applicant estimated the level of intake of the heat-inactivated starter culture 
(B. xylanisolvens DSM 23964) via the consumption of yoghurts, which represents the highest potential 
intake of the NF. The estimated ingestion of non-viable cells of B. xylanisolvens in fermented milk 
products expressed as CFU was similar for the different age groups. On a per kilogram body weight 
per day basis it was highest for two- to five-year-old old children (mean 2  1010 CFU/kg bw per day; 
90
th
 percentile 3.8  1010 CFU/kg bw per day), which could be considered as a conservative scenario 
(Table 1). The 90
th
 percentile intake of 964 mg of non-fat milk solids from all fermented milk 
products, combined per kilogram body weight by children aged 2–5 years, would correspond to an 
intake of 3.4  1010 CFU of non-viable B. xylanisolvens per kilogram body weight per day for this 
population group. 
Table 1:  Estimated intake of non-fat milk solids and heat-inactivated B. xylanisolvens DSM 23964 
for the mean and the 90
th
 percentile consumption of yoghurt by age group 
Age group, 
gender 
Non-fat milk solids B. xylanisolvens DSM 23964 
g per day 
mg/kg bw per 
day 
Cells per day 
(a)
 Cells/kg bw per day 
Mean 90
th
 Mean 90
th
 Mean 90
th
 Mean 90
th
 
2–5 years  9.5 16.5 570 1084 3.4  1011 5.9  1011 2.0  1010 3.8  1010 
6–10 years  9.6 20.5 357 793 3.4  1011 7.3  1011 1.3  1010 2.9  1010 
11–19 years, m  12.7 25.0 (a) 225 475 (a) 4.5  1011 8.9  1011 0.80  1010 1.7  1010 
11–19 years, f  11.0 23.1 190 403 3.9  1011 8.1  1011 0.68  1010 1.4  1010 
> 20 years, m  12.1 23.1 147 282 4.3  1011 8.2  1011 0.52  1010 1.0  1010 
> 20 years, f  11.7 22.5 171 339 4.2  1011 8.1  1011 0.61  1010 1.2  1010 
All  11.4 22.5 225 464 4.1  1011 7.9  1011 0.80  1010 1.6  1010 
(a)
 Calculated on basis of the assumption that 100 ml heat-treated fermented low-fat or non-fat milk product contains 14 g 
non-fat milk solids and 0.5  1012 CFU of non-viable B. xylanisolvens DSM 23964. 
5. Nutritional information on the novel food 
The compositional data provided by the applicant includes information on macronutrients (Table 2). 
Table 2:  Composition of spray-dried skimmed milk cultured with B. xylanisolvens DSM 23964 and 
commercial fermented milk products 
Composition (g/100 g) 
Skimmed milk 
with 
B. xylanisolvens 
Fermented milk 
L. reuteri 
(a)
 
Fermented milk 
L. rhamnosus 
(a)
 
Low-fat yoghurt 
(b)
 
Carbohydrates  48.8 37.3 41.0 35.7 
 Glucose  3.6 0.4 < 0.10 n.a. 
 Fructose  < 0.10 < 0.10 < 0.10 n.a. 
 Saccharose  1.5 0.15 0.15 n.a. 
 Maltose  < 0.10 < 0.10 < 0.10 n.a. 
Protein
 (c)
 30.9 32.5 32.1 42.6 
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Composition (g/100 g) 
Skimmed milk 
with 
B. xylanisolvens 
Fermented milk 
L. reuteri 
(a)
 
Fermented milk 
L. rhamnosus 
(a)
 
Low-fat yoghurt 
(b)
 
Fat
 (d)
 0.4 13.9 14.0 0.98 
 Saturated  0.21 9.78 9.86 n.a. 
 MUFAs  0.12 3.27 3.28 n.a. 
 PUFAs  0.014 0.36 0.36 n.a. 
 trans-fats  0.012 0.36 0.37 n.a. 
Ash  8.17 6.78 6.73 8.8 
Total acid
 (e)
 4.84 5.62 2.51 11.9 
Purine nitrogen  0.025 0.012 0.013 n.a. 
Water  6.86 3.91 3.67 – 
(a): Product prepared by Avitop (similar process as that for skimmed milk fermented with B. xylanisolvens, except for the 
applied starter culture and the addition of glucose). 
(b): Souci et al., 1994—values calculated on dry matter basis. 
(c): Kjeldahl analysis (N  6.25); Codex Standard 243-2003: > 2.7 %. 
(d): Weibull–Stoldt analysis; Codex Standard 243-2003: < 10 %. 
(e): Titration-calculated as citric acid; Codex Standard 243-2003: > 0.3 %. 
n.a., not available; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 
 
In order to address effects of the long heat treatment process (75 °C for 60 minutes) on the vitamins 
for which fermented milk products could be a relevant source and on the extent of Maillard reactions 
which could effect the lysine content, EFSA asked the applicant to provide analyses of the content, in 
at least three batches, of vitamins B2 and B12 and lysine, as well as furosine, as a marker for Amadori 
products formed from early Maillard reactions before and after this heat treatment. The results of these 
analyses are provided in Table 3. According to these results, there is no effect of this heat treatment 
step on the vitamin B2 and vitamin B12 content. The measurement of ‘free lysine’ is considered not an 
appropriate parameter to address potential lysine loss by Maillard reaction, but, considering the results 
for furosine, the Panel considers that the one-hour heat treatment does not have a significant effect on 
the lysine content. 
Table 3:  Effect of the heat treatment (75 °C for 60 minutes) on the content of certain heat-sensitive 
nutrients and furosine in UHT low-fat milk before and after fermentation with B. xylanisolvens DSM 
23964 
 
UHT 
control 
Batch No UHT 
control 
Batch No UHT 
control 
Batch No 
1 2 3 1 2 3 1 2 3 
0 min 5 min 60 min 
Vitamin B2 
(mg/l) 
1.8 1.6 1.7 1.7 1.9 2.1 2.1 1.9 1.7 1.8 1.7 1.7 
Vitamin B12 
(µg/l) 
1.4 1.5 1.4 1.3 1.3 1.4 1.3 1.3 1.3 1.3 1.1 1.2 
Free lysine 
(mg/l) 
3.5 25.7 25.5 24.8 2.7 23.1 24.2 23.5 3.1 21.6 18.9 18.8 
Furosine 
(mg/kg) 
26.6 26.6 26.1 24.8 27.1 25.6 25.9 26.0 29.0 26.9 27.0 27.5 
 
In response to the question raised by EFSA regarding the lactose content of the NF, the applicant 
stated that lactose content has not been analysed, but that it could be estimated by the difference 
between the figures given for total carbohydrates and the specifically determined sugars (glucose, 
fructose, saccharose and maltose) provided in Table 2. The applicant estimated that 43.7 % of the total 
solids of fermented milk would be lactose, which would be within the range of low-fat dried dairy 
products available on the market.  
Based on the information provided on the production process and composition, the Panel considers 
that consumption of the NF is not nutritionally disadvantageous.  
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6. Microbiological information on the novel food 
The applicant and the FSAI noted that the use of Bacteroides in food production was not reported in 
the EU before May 1997 and that B. xylanisolvens was not assessed under the Qualified Presumed 
Safety (QPS) scheme at the time when this novel food was assessed by Member States. However, a 
QPS assessment is triggered when EFSA receives an application for a novel bacterial strain or a 
product which intentionally contains novel bacteria. Thus, in 2014, the EFSA Panel on Biological 
Hazards has assessed B. xylanisolvens under the QPS scheme (EFSA BIOHAZ Panel, 2014). The QPS 
assessment by the Panel on Biological Hazards is independent of the assessment of application 
dossiers, which remain the responsibility of the EFSA Panel to which the risk assessment is mandated. 
The QPS assessment therefore does not consider dossier-specific data such as the production process 
(e.g. pasteurisation or inactivation steps) or unpublished data contained in application dossiers. 
Further, the EFSA Panel on Biological Hazards noted that, although no safety concerns have been 
observed (as only a β-lactamase resistance gene (cepA) has been identified in the genomic DNA, 
which is unlikely to be transferable), the studies published on B. xylanisolvens are not sufficient for the 
inclusion of this species in the QPS list. 
In addition to the information given in section 1 on the identification and phenotypic and genotypic 
characterisation of B. xylanisolvens DSM 23964, the information provided by the applicant also 
contained an examination of the presence of antibiotic resistance and plasmids, potential virulence 
genes, extracellular enzymes and pathogenic factors, and determination of the adhesion of 
B. xylanisolvens DSM 23964 to Caco-2 cells (Ulsemer et al., 2012a). 
According to the results of the investigations by Ulsemer et al. (2012a), B. xylanisolvens DSM 23964 
is resistant to -lactam antibiotics owing to the presence of -lactamase activity encoded by the cepA 
gene. This gene (encoding a class 2e cephalosporinase) has not been previously associated with 
mobile elements (e.g. conjugative transposon) that facilitate gene transfer and was identified in the 
genomic DNA of this strain. This resistance to -lactam antibiotics is widespread among species of the 
genus Bacteroides (Wexler, 2007; Eitel, 2013). A test determining plasmids with a detection limit of 
about 150 kb and using Escherichia coli strains containing low-copy-number plasmids as positive 
controls was negative, suggesting the chromosomal location of the -lactamase gene. 
Bacteroides xylanisolvens DSM 23964 was sensitive to the antibiotics metronidazole, meropenem 
agents and clindamycin. 
The Panel considers that, owing to the chromosomal location of the cepA gene, the absence of 
detectable plasmids (with a detection limit of 150 kb) and the heat inactivation, gene transfer is not 
expected to occur. 
Analyses of B. xylanisolvens DSM 23964 for eight potential virulence genes, as identified for 
B. fragilis, B. caccae and B. ovatus, provided negative results (Ulsemer et al., 2012a). The established 
strains and clinical isolates of these three species were used as positive controls for potential virulence 
factors and production of extracellular enzymes. 
The most relevant exoenzyme activities were analysed by means of PCR (for the neuraminidase gene) 
or with enzymatic assays. Bacteroides xylanisolvens DSM 23964 showed no DNase, chondroitinase, 
hyaluronidase or neuraminidase activity and only very weak β-haemolytic and collagenase activities 
(Ulsemer et al., 2012a). 
Bacteroides xylanisolvens DSM 23964 differs from three B. ovatus strains, DSM 1896 and two 
clinical isolates (MN23 and MN7) in several of the investigated characteristics: B. ovatus strains were 
positive for the cefoxitin (cfxA) gene, which was reported to be horizontally transmitted (in addition to 
cepA) and were used as a positive controls for neuraminidase, haemolysin and collagenase activity. 
Bacteroides xylanisolvens DSM 23964 was negative in an adhesion test with Caco-2 cells compared 
with L. acidophilus DSM 9126 and B. fragilis DSM 1396, which were used as positive controls. 
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Based on available information as well as data on B. xylanisolvens DSM 23964 provided by the 
applicant, the German Federal Institute for Occupational Safety and Health (BAuA) allocated 
B. xylanisolvens to risk group 1 (RG1), which contains those microorganisms which in their viable 
form can be handled without a health risk to humans (and other vertebrates), according to current 
knowledge (BAuA, 2011). Thus, B. xylanisolvens DSM 23964 is considered to belong to those 
biological agents that are unlikely to cause human disease, as defined in Directive 2000/54/EC on the 
protection of workers from risks related to exposure to biological agents at work (Deutsche 
Gesetzliche Unfallversicherung, 2010). 
The Panel considers that the data provided are sufficient and do not raise safety concerns with regard 
to the microbiological risks of the NF. 
7. Toxicological information on the novel food  
The toxicological evaluation covered the genotoxicity and subchronic toxicity of heat-inactivated and 
non-heat-inactivated B. xylanisolvens DSM 23964 examined by studies that followed the appropriate 
OECD guidelines and GLP. In addition, an abscess formation test was conducted in mice to 
investigate the potential pathogenicity of the B. xylanisolvens DSM 23964. 
7.1. Genotoxicity 
The applicant provided the study reports on an in vitro test for gene mutations (Ames test) and on an 
in vitro chromosome aberration test using lyophilisate containing purified live and heat-inactivated B. 
xylanisolvens DSM 23964 in accordance with OECD Guidelines 471 and 473 with negative outcomes 
(Leuschner 2010a, b; Ulsemer et al., 2012b). However, the Panel considers that there is no rationale 
for genotoxicity testing of live and heat-inactivated microorganisms such as B. xylanisolvens DSM 
23964. 
7.2. Subchronic toxicity 
The toxicity of B. xylanisolvens DSM 23964 was examined in a 90-day oral toxicity study following 
OECD Guideline 408 (Leuschner, 2010c; Ulsemer et al., 2012b). Five dose groups (10 male and 10 
female animals per group) were studied: each mouse received by gavage daily doses of either 1  109 
viable, 1  1010 viable, 1  1011 viable or 1  1011 heat-inactivated cells of B. xylanisolvens DSM 
23964 or the vehicle (control). No mortality was noted during the course of the study. No differences 
between groups were found in behaviour, external clinical appearance, faeces and functional 
observations between the animals treated with viable or inactivated B. xylanisolvens DSM 23964. Nor 
were any differences in body weight or food or water consumption observed. No treatment-related 
effects were found in the haematological and clinical biochemical, ophthalmological, macroscopic 
post-mortem examinations, organ weights or histology. As for genotoxicity testing, the Panel 
considers that there is no rationale for toxicity testing of live and heat-inactivated microorganisms 
such as B. xylanisolvens DSM 23964.  
7.3. Abscess formation test 
Bacteroides xylanisolvens DSM 23964 was also studied in an intraperitoneal abscess formation model 
in mice (Toutounian, 2010, unpublished; Ulsemer et al., 2012a). Twenty-six male Webster mice were 
used for this experiment. The mice were divided into seven groups, of which three groups received an 
intraperitoneal injection of 200 µl of viable B. xylanisolvens DSM 23964 at three different doses 
ranging from 5  106 to 1  109 CFU per mouse. Three groups received the same amounts of 
B. fragilis RMA 6791 as a positive control and one group received sterilised supernatant of phosphate-
buffered saline-suspended rat faeces (negative control). B. fragilis RMA 6791 induced abscess 
formation in all three dose groups, confirmed by species-specific PCR, while no mouse receiving 
B. xylanisolvens DSM 23964 developed an abscess.  
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7.4. Human data 
The safety of the B. xylanisolvens fermented milk product was addressed in one pilot study and a 
randomised controlled trial (RCT).  
In a three-week non-controlled pilot study, two groups, each of 10 male and 10 female volunteers, 
consumed daily portions of 100 ml heat-treated low-fat milk cultured with B. xylanisolvens (5  1011 
or 8  1011 inactivated cells/portion) and flavoured with cherry pulp. The product was well tolerated 
and no significant effects were observed in the parameters (haematological analyses, 
immunoglobulins, cytokines, phagocytosis, NK cells) monitored (Ulsemer et al., 2012c). 
In a subsequent RCT over six weeks, 140 adult volunteers were divided into four groups, which 
received, once per day, (1) milk powder as a placebo or spray-dried heat-treated milk fermented by 
B. xylanisolvens DSM 23964; (2) 1  1010 CFU B. xylanisolvens DSM 23964; (3) 2.5  1011 CFU 
B. xylanisolvens DSM 23964; or (4) 1  1012 CFU B. xylanisolvens DSM 23964 that had been 
inactivated. No gastrointestinal problems occurred. No effects on the clinical, haematological and 
immunological parameters analysed were observed (Ulsemer et al., 2012c). No information on the 
source of the milk used for fermentation was provided in the article, but the applicant informed EFSA 
that this was cow’s milk. 
In addition to the human studies, the applicant also conducted an extensive literature search and 
investigations of the Center for Disease Control and Prevention and the Food and Drug 
Administration’s databases, including Medwatch, which did not reveal any report of food poisoning or 
human disease associated with B. xylanisolvens.  
8. Allergenicity 
No data regarding allergenicity of the novel food were provided by the applicant.  
The Panel notes that the effects of heat treatment of milk on its allergenicity have been considered by 
EFSA (EFSA NDA Panel, 2014).  
Although no information has been provided to allow conclusions to be drawn on the risk of allergic 
reactions caused by the NF, the Panel considers that it is unlikely that the allergenic potential of the 
NF is dissimilar to that of other fermented dairy products. 
DISCUSSION  
The NF products pertaining to this application are heat-treated low-fat and skimmed milk products, 
including spray-dried products, fermented with B. xylanisolvens DSM 23964. The applicant noted that 
the NF should comply with the Codex Standard for fermented milk and fermented milk products and 
with microbiological criteria in EU regulations set for fermented milk products. In addition, the 
absence of viable B. xylanisolvens DSM 23964 was proposed by the applicant to serve as the 
specification of this NF.  
Bacteroides xylanisolvens is a commensal bacterium of the human intestinal microbiota and has been 
reported to be one of most abundant Bacteroides species in the human intestine. Bacteroides 
xylanisolvens DSM 23964 has been isolated from the faeces of a healthy human adult. It was 
characterised at strain level and differentiated from the type strain B. xylanisolvens DSM 18836. The 
sequence analysis of a 480-bp fragment of the 16S rRNA gene and DNA–DNA hybridisation, as well 
as RAPD analysis, were used to identify this bacterium at species and strain level, respectively. The 
biochemical identification and characterisation of B. xylanisolvens DSM 23964 included the detection 
of 12 enzyme activities and 6 metabolites. The Panel considers the information provided on the 
identity of B. xylanisolvens DSM 23964 to be sufficient. 
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Pasteurised or UHT skimmed or low-fat milk is used for the fermentation process with 
B. xylanisolvens DSM 23964. After fermentation the product is heat treated for one hour at 75 °C to 
ensure the absence of viable B. xylanisolvens DSM 23964. The Panel notes that the production process 
encompasses standard techniques used by the dairy industry and considers that it is sufficiently 
described by the applicant and does not give rise to safety concerns. The Panel also considers that the 
information provided on the production process and on its effect on the content of vitamins B2 and B12 
and furosine of the heat-treated fermented milk products do not give rise to concerns regarding 
disadvantageous nutritional effects.  
The applicant provided studies evaluating the antibiotic resistances and the presence of related genes 
and plasmids, potential virulence genes, extracellular enzymes and pathogenic factors and the 
adhesion of B. xylanisolvens DSM 23964 to Caco-2 cells. The cepA gene conferring resistance to -
lactam antibiotics was identified in the genomic DNA of this strain. The Panel notes that this 
resistance to -lactam antibiotics is widespread among species of the genus Bacteroides and that the 
cepA gene has not been previously associated with mobile elements (e.g. conjugative transposon) that 
facilitate gene transfer. The Panel considers that the chromosomal location of cepA, the absence of 
detectable plasmids (detection limit 150 kb) and the heat inactivation make it unlikely that horizontal 
gene transfer occurs from the starter culture. Bacteroides xylanisolvens DSM 23964 did not show 
potential pathogenic features and adverse enzymatic activities such as DNase, chondroitinase, 
hyaluronidase or neuraminidase activity and only very weak β-haemolytic and collagenase activity. 
An abscess formation test with viable B. xylanisolvens DSM 23964 cells was negative. The Panel 
considers that the microbiological information does not give rise to safety concerns. 
According to the intake estimate performed by the applicant, the ingestion of inactivated (non-viable) 
cells of B. xylanisolvens, expressed as CFUs, ingested with fermented milk products was similar for 
the different age groups. On a kilogram body weight per day basis, intake was estimated to be highest 
in two- to five-year-old children, with mean and 90
th
 percentile values of 2  1010 CFU/kg bw per day 
and 3.8  1010 CFU/kg bw per day, respectively. These estimates are based on the conservative 
assumption that B. xylanisolvens DSM 23964 is used for all consumed fermented milk products. 
The Panel also notes a pilot study and a RCT in which 140 adult volunteers received daily doses of a 
spray-dried heat-treated fermented milk product providing up to 1  1012 inactivated CFU of 
B. xylanisolvens DSM 23964, which is above the 90
th 
percentile intake of a conservative intake 
scenario. No haematological, immunological, gastrointestinal or other clinical adverse effects were 
observed related to the treatment in these two human studies.  
Although no information has been provided to allow conclusions to be drawn on the risk of allergic 
reactions caused by the NF, the Panel considers that it is unlikely that the allergenic potential of the 
NF is dissimilar to that of other fermented dairy products. 
CONCLUSIONS 
The Panel concludes that the novel food ‘heat treated milk products fermented with Bacteroides 
xylanisolvens DSM 23964’ is safe for the proposed uses and at the proposed use levels.  
DOCUMENTATION PROVIDED TO EFSA 
1. Dossier on ‘pasteurised milk products fermented with Bacteroides xylanisolvens DSM 23964’ 
by Bioresco on behalf of Avitop GmbH, received on 10 April 2014. Additional information was 
provided on 10 October and 28 November 2014. 
2. Letter from the European Commission to the European Food Safety Authority with the request 
for an opinion on the safety of ‘pasteurised milk products fermented with Bacteroides 
xylanisolvens as a novel food’. Ref. Ares (2014)1132458-10/04/2014. 
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3. Initial assessment report carried out by the competent authority of Ireland ‘Safety assessment of 
pasteurised milk products fermented with Bacteroides xylanisolvens DSM 23964’. 
4. Member States’ comments and objections. 
5. Response by the applicant to the initial assessment report and the Member States’ comments 
and objections. 
REFERENCES 
Andersson I and Oete R, 1994. Nutritional quality of pasteurised milk. Vitamin B12, folate and 
ascorbic acid content during storage. International Dairy Journal, 4, 161–172.  
BAuA (Bundesanstalt für Arbeitsschutz und Arbeitsmedizin), 2011. Ausschuss für Biologische 
Arbeitsstoffe (ABAS) Unterausschuss 3. Einstufung der Spezies Bacteroides xylanisolvens und des 
Stammes Bacteroides xylanisolvens (Bacteroides ovatus) CTC1 in eine Risikogruppe. 
Brook I, 1989. Pathogenicity of the Bacteroides fragilis group. Annals of Clinical Laboratory Science, 
19, 360–376. 
Chassard C, Delmas E, Lawson PA and Bernalier-Donadille A, 2008. Bacteroides xylanisolvens sp. 
nov., a xylan-degrading bacterium isolated from human faeces. International Journal of Systemic 
and Evolution Microbiology, 58, 1008–1013. 
Culebras E, Rodriguez-Avial I, Betriu C, Gómez C and Picazo JJ, 2012. Rapid identification of 
clinical isolates of Bacteroides species by matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry. Anaerobe, 18, 163–165.  
Deutsche Gesetzliche Unfallversicherung (2010). Riegel HJ, 2010. Letter of DGUV to Dr Philippe 
Ulsemer, dated 10 September 2010. 
DSMZ (German Resource Centre for Biological Material), 2010. Letter of DSMZ GmbH to Glycotope 
GmbH, dated 6 September 2010. 
EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), 2014. Statement on the update of the list 
of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 1: 
Suitability of taxonomic units notified to EFSA until October 2014. EFSA Journal 
2014;12(12):3938, 18 pp. doi:10.2903/j.efsa.2014.3938  
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific 
Opinion on the evaluation of allergenic foods and food ingredients for labelling purposes. EFSA 
Journal 2014;12(11):3894, 286 pp. doi:10.2903/j.efsa.2014.3894  
Eitel Z, Sóki J, Urbán E, Nagy E, and the ESCMID Study Group on Anaerobic Infection, 2013. The 
prevalence of antibiotic resistance genes in Bacteroides fragilis group strains isolated in different 
European countries. Anaerobe, 21, 43–49. doi: 10.1016/j.anaerobe.2013.03.001 
FAO (Food and Agriculture Organization of the United Nations), 2011. Codex Alimentarius. Milk and 
milk products, 2nd edition. Codex Standard for fermented milks, p. 6. Available online: 
http://www.fao.org per dayocrep/015/i2085e/i2085e00.pdf 
Finegold SM, Sutter VL and Mathisen GE, 1983. Normal indigenous intestinal flora. In: Human 
intestinal microflora in health and disease. Ed. Hentges DJ. Academic Press, New York, USA, 3–
32. 
Finot PA, Deutsch R and Bujard E, 1981. The extent of the Maillard reaction during the processing of 
milk. Progress in Food and Nutrition Sciences, 5, 345–355. 
Gliquem H and Birlouez-Aragon J, 2005. Effects of sterilization, packaging and storage on vitamin C 
degradation, protein denaturation and glycation in fortified milks. Journal of Dairy Science, 88, 
891–899. 
Safety of milk products fermented with B. xylanisolvens DSM 23964  
 
EFSA Journal 2015;13(1):3956 16 
Kulagina EV, Efimov BA, Maximov PY, Kafarskaia LI, Chaplin AV and Shkoporov AN, 2012. 
Species composition of Bacteroidales order bacteria in the feces of healthy people of various ages. 
Bioscience, Biotechnology and Biochemistry, 76, 167–171. 
Leuschner J, 2010a. Mutagenicity study of Bacteroides xylanisolvens CTC1 in the Salmonella 
typhimurium reverse mutation assay (in vitro). LPT Report No 22355, 26 August 2010. 
Unpublished report of the Laboratory of Pharmacology and Toxicology, Hamburg, Germany.  
Leuschner J, 2010b. In vitro assessment of the clastogenic activity of Bacteroides xylanisolvens in 
cultured human peripheral lymphocytes. LPT Report No 22356 dated 26 August 2010. 
Unpublished report of the Laboratory of Pharmacology and Toxicology, Hamburg, Germany.  
Leuschner J, 2010c. Repeated dose 90-day oral toxicity study of Bacteroides xylanisolvens CTC−1 in 
mice. LPT Report No 22171 dated 23 September 2010. Unpublished report of the Laboratory of 
Pharmacology and Toxicology, Hamburg, Germany.  
Marconi E and Panfili G, 1998. Chemical composition and nutritional properties of commercial 
products of mare milk powder. Journal of Food Composition and Analysis, 11, 178–187. 
Marschal M, Schumacher U and Autenrieth I, 2011. Improvement of identification of anaerobes by 
MALDI-TOF mass spectrometry analysis. Proceedings of the 21st European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID), 27th International Congress of Chemotherapy 
(ICC), Milan, Italy. 9 May 2011. 
Ponnusamy K, Choi JN, Kim J, Lee SY and Lee CH, 2011. Microbial community and metabolomic 
comparison of irritable bowel syndrome feces. Journal of Medical Microbiology, 60, 817–827. 
Salyers A, 1984. Bacteroides of the human lower intestinal tract. Annual Reviews of Microbiology, 
38, 293–313.  
Sanchez E, Laparra JM and Sanz Y, 2012. Discerning the role of Bacteroides fragilis in celiac disease 
pathogenesis. Applied and Environmental Microbiology, 78, 6507–6515. doi: 
10.1128/AEM.00563-12. 
Toutounian K, 2008. Pasteurization of fermented milk product produced with B. xylanisolvens DSM 
23964. Internal Report of Avitop GmbH, dated 28 September 2008. 
Toutotunian K, 2010. Investigation of the in-vivo pathogenicity of Bacteroides xylanisolvens CTC-1 
(abscess formation). Internal Report of Avitop GmbH, dated 19 August 2010. 
Ulsemer P, Toutounian K, Schmidt J, Karsten U and Goletz S, 2012a. Preliminary safety evaluation of 
a new Bacteroides xylanisolvens isolate. Applied and Environmental Microbiology, 78, 528–535. 
Ulsemer P, Toutounian K, Schmidt J, Leuschner J, Karsten U and Goletz S, 2012b. Safety assessment 
of the commensal strain Bacteroides xylanisolvens DSM 23964. Regulatory Toxicology and 
Pharmacology, 62, 336–346. 
Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A and Goletz S, 2012c. Safety and 
tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults. Beneficial Microbes, 3, 99–
111. 
Van Boekel MAJS, 1998. Effect of heating on Maillard reactions in milk. Food Chemistry, 62, 403–
414. 
Wexler HM, 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clinical Microbiology 
Reviews, 20, 593–621. 
Wijesinha-Bettoni R and Burlingame B, 2013. Milk and dairy product composition. In: Milk and dairy 
products in human nutrition. Eds Muelhoff E, Bennett A and McMahon. FAO, Rome, 41–102.  
Zitomersky NL, Coyne MJ and Comstock LE, 2011. Longitudinal analysis of the prevalence, 
maintenance and IgA response to species of the order Bacteroidales in the human gut. Infection and 
Immunity, 79, 2012–2020.  
Safety of milk products fermented with B. xylanisolvens DSM 23964  
 
EFSA Journal 2015;13(1):3956 17 
Appendix A.  Estimated daily intake of milk non-fat solids from fermented milk products by the US population, NHANES 2003–2008 
Fermented milk 
category and 
subpopulation 
Unweighted 
sample size 
Unweighted 
number of 
users 
% 
Users 
Estimated intake of non-fat milk solids 
(g per day) (mg/kg bw per day) 
Per capita Per user Per capita Per user 
Mean 90
th
 Mean 90
th
 Mean 90
th
 Mean 90
th
 
Yogurt  
US 2+ years  22 602 2 727 13 1.5 5.7 11.4 22.5 30 87 225 464 
Children 2–5 years  2 149 467 25 2.4 9.6 9.5 16.5 144 529 570 1084 
Children 6–10 years  2 202 311 15 1.4 4.7 9.6 20.5 52 159 357 793 
Males 11–19 years  2 667 155 8 1.0 0 12.7 25.0 (a) 17 0 225 475 (a) 
Females 11–19 years  2 719 257 10 1.1 0.7 11.0 23.1 19 13 190 403 
Males 20+ years  6 113 521 9 1.1 0 12.1 23.1 14 0 147 282 
Females 20+ years  6 752 1 016 16 1.9 8.1 11.7 22.5 27 116 171 339 
Buttermilk and acidophilus milk  
US 2+ years  22 602 4 144 20 0.1 0.3 0.7 1.0 1.9 3.9 9.8 15.4 
Children 2–5 years 2 149 308 17 0.1 0.1 0.3 0.7 2.9 6.2 17.0 35.7 
Children 6–10 years  2 202 425 20 0.1 0.2 0.3 0.7 2.2 6.6 11.4 27.8 
Males 11–19 years  2 667 427 16 0.1 0.2 0.5 1.1 1.2 3.1 7.2 17.0 
Females 11–19 years  2 719 552 22 0.1 0.3 0.4 0.8 1.4 4.5 6.2 14.6 
Males 20+ years  6 113 1 007 17 0.2 0.3 1.1 1.4 2.3 3.0 13.7 14.8 
Females 20+ years  6 752 1 425 23 0.1 0.3 0.5 0.9 1.6 4.1 7.1 12.7 
All fermented milk products combined  
US 2+ years  22 602 6 359 30 1.6 6.3 5.4 15.3 31 94 104 288 
Children 2–5 years  2 149 699 38 2.4 9.7 6.4 14.9 146 531 383 964 
Children 6–10 years  2 202 675 32 1.5 4.7 4.6 13.8 54 161 171 500 
Males 11–19 years  2 667 549 22 1.1 0.7 4.8 15.0 19 11 84 247 
Females 11–19 years  2 719 758 30 1.2 1.4 4.0 13.8 21 26 69 233 
Males 20+ years 6 113 1 454 25 1.3 1.4 5.4 17.4 16 16 65 207 
Females 20+ years  6 752 2 224 35 2.0 8.7 5.7 15.5 29 119 82 243 
(a): Estimates may be less statistically reliable based on the sample size. 
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ABBREVIATIONS 
ATCC  American Type Culture Collection 
bw body weight 
DSMZ German Resource Centre for Biological Material 
FAO Food and Agriculture Organisation of the United Nations 
GMP  Good Manufacturing Practice 
HACCP Hazard Analysis and Critical Control Point 
JCM Japan Collection of Microorganisms 
kb kilobase 
NF novel food 
PCR polymerase chain reaction 
RAPD random amplified polymorphic DNA 
